FENC - NASDAQ

Fennec Pharmaceuticals Inc.

FENC·NASDAQ

$9.35

-6.3%

HealthcareBiotechnology

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$267.13M

EPS-0.3600

P/E Ratio-25.96

Earnings Date08/13/2026

70.07M

Assets

56%

3Y+160.0%

5Y+123.0%

10Y+1664.0%

35.02M

Total Liabilities

-31%

3Y+19.0%

5Y+1392.0%

10Y+8610.0%

35.05M

Total Equity

-697%

3Y-1464.0%

5Y+21.0%

10Y+882.0%

Fennec Pharmaceuticals Inc. Funding & Solvency Profile

FENC · NASDAQ

Current Assets

Cash & Cash Equivalents36.72M

Net Receivables23.18M

Inventory1.56M

Other Current Assets1.37M

Total Current Assets67 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets3.50M

Total Non-Current Assets4 M

Total Assets

70.07M

Financial Health Analysis

Current Ratio

6.34x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.00x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

56 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

95% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Fennec Pharmaceuticals Inc. Balance Sheet

FENC • NASDAQ

Fennec Pharmaceuticals Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	36.7M	26.6M	13.3M	23.8M	21.1M	30.3M	13.7M	22.8M	28.3M	3.9M	942K	2.3M	1.7M	2.3M	5.3M	5.9M	685K	5.3M	16.2M	5.7M
Cash & Short-Term Investments	36.7M	26.6M	13.3M	23.8M	21.1M	30.3M	13.7M	22.8M	28.3M	3.9M	942K	2.3M	1.7M	2.3M	5.3M	5.9M	685K	5.3M	16.2M	5.7M
Net Receivables	23.2M	12.9M	8.8M	1.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	69K	139K	185K	103K
Accounts Receivables	23.2M	12.9M	8.8M	1.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	69K	6K	21K	32K
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	133K	164K	71K
Inventory	1.6M	1.1M	2.2M	576K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	75K	123K	185K	94K
Prepaids	3.7M	3.1M	2.6M	770K	1M	797K	226K	168K	128K	43K	76K	48K	81K	56K	35K	38K	75K	71K	130K	41K
Other Current Assets	1.4M	466K	44K	63K	253K	276K	8K	1K	13K	3K	1K	17K	8K	6K	19K	8K	4K	28K	84K	86K
Total Current Assets	66.6M	44.1M	26.9M	26.7M	22.4M	31.4M	13.9M	23M	28.4M	4M	1M	2.4M	1.8M	2.4M	5.4M	6M	833K	5.6M	16.6M	5.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	421K	648K	293K
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10M
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10M
Other Non-Current Assets	3.5M	822K	6K	211K	27K	0.0	262K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	440K
Total Non-Current Assets	3.5M	822K	6K	211K	27K	0.0	262K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	421K	648K	10.7M
Total Assets	70.1M	44.9M	26.9M	26.9M	22.4M	31.4M	14.1M	23M	28.4M	4M	1M	2.4M	1.8M	2.4M	5.4M	6M	833K	6.1M	17.2M	16.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	4.6M	3.2M	3.8M	2.4M	777K	1.6M	1.6M	1M	855K	244K	297K	308K	212K	259K	342K	272K	318K	547K	532K	2.1M
Accounts Payable	4.6M	3.2M	3.8M	2.4M	777K	1.6M	1.6M	1M	855K	244K	297K	308K	212K	259K	342K	272K	318K	547K	532K	2.1M
Accrued Expenses	0.0	3.4M	3.8M	2.2M	877K	776K	659K	605K	622K	125K	92K	132K	132K	423K	52K	195K	70K	1.9M	1.8M	2.6M
Capital Lease Obligations (Current)	0.0	2K	21K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6M
Deferred Revenue	247.5K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	5.6M	248K	0.0	0.0	0.0	0.0	0.0	0.0	167K	33K	82K	1.3M	2.9M	6.6M	5.1M	10.5M	32K	0.0	40K	0.0
Total Current Liabilities	10.5M	6.9M	7.6M	4.6M	1.7M	2.3M	2.3M	1.6M	1.6M	402K	471K	1.8M	3.2M	7.3M	5.5M	10.9M	420K	2.4M	2.4M	4.7M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	19.3M	30.9M	24.9M	5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6M
Other Non-Current Liabilities	24.5M	24.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7K	577K	659K	665K
Total Non-Current Liabilities	24.5M	43.9M	30.9M	24.9M	5M	0.0	0.0	1M	855K	244K	297K	308K	212K	259K	342K	272K	7K	577K	659K	4.3M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1M	-855K	-244K	-297K	-308K	-212K	-259K	-342K	-272K	0.0	0.0	0.0	0.0
Capital Lease Obligations	0.0	2K	23K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	35M	50.8M	38.5M	29.5M	6.6M	2.3M	2.3M	1.6M	1.6M	402K	471K	1.8M	3.2M	7.3M	5.5M	10.9M	427K	3M	3.1M	9M
SHAREHOLDERS' EQUITY
Common Stock	189.6M	145.6M	144.3M	142.6M	140.8M	140.7M	106.4M	106.4M	103M	74.5M	69.2M	68.7M	66.8M	66M	66M	64.9M	64.9M	64.9M	64.9M	46.5M
Additional Paid-In Capital	73.6M	67M	62.1M	56.8M	53.2M	49.2M	48.3M	44.9M	43.8M	42.1M	41.4M	41.6M	39.2M	38.4M	38.1M	37.7M	100.2M	99.8M	97.3M	71M
Retained Earnings	-229.4M	-219.7M	-219.2M	-203.2M	-179.5M	-162.1M	-144M	-131.3M	-121.4M	-114.3M	-111.5M	-110.9M	-108.7M	-110.5M	-105.4M	-108.8M	-101M	-98M	-84.4M	-71.5M
Accumulated Other Comprehensive Income/Loss	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	1.2M	5.9M
Other Total Stockholders' Equity	0.0	1.0	0.0	25.8K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-64.9M	-64.9M	0.0	8M
Total Stockholders' Equity	35.1M	-5.9M	-11.6M	-2.6M	15.8M	29.1M	11.9M	21.3M	26.8M	3.6M	548K	613K	-1.5M	-5M	-120K	-4.9M	406K	3.1M	14.1M	7.6M
Total Equity	35.1M	-5.9M	-11.6M	-2.6M	15.8M	29.1M	11.9M	21.3M	26.8M	3.6M	548K	613K	-1.5M	-5M	-120K	-4.9M	406K	3.1M	14.1M	7.6M
SUMMARY
Total Liabilities & Equity	70.1M	44.9M	26.9M	26.9M	22.4M	31.4M	14.1M	23M	28.4M	4M	1M	2.4M	1.8M	2.4M	5.4M	6M	833K	6.1M	17.2M	16.6M
Total Debt	0.0	19.3M	31M	24.9M	5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-36.7M	-7.3M	17.7M	1.1M	-16.1M	-30.3M	-13.7M	-22.8M	-28.3M	-3.9M	-942K	-2.3M	-1.7M	-2.3M	-5.3M	-5.9M	-685K	-5.3M	-16.2M	-5.7M
Shares Outstanding	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897	27,476,897

SEC Filings

FENC - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 22, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 18, 2026	May 18, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 27, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 22, 2026	April 22, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 07, 2026	April 07, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 27, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 16, 2026	March 16, 2026	2026	View Filing

Showing 1 to 10 of 267 filings

Related Guides

Blog Categories

Continue your FENC research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.